Compare

Agios Pharmaceuticals, Inc. vs Integrated Biopharma Inc vs Nektar Therapeutics vs Ocular Therapeutix, Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearAgios Pharmaceuticals, Inc.
AGIO
Integrated Biopharma Inc
INBP
Nektar Therapeutics
NKTR
Ocular Therapeutix, Inc
OCUL
Year ended2025-12-312025-06-302025-12-312025-12-31
Revenue$54.03M$54.35M$55.23M$51.95M
Revenue growth (YoY)+48.0%+8.0%-43.9%-18.5%
Gross margin88.3% (computed)10.2%n/a87.3% (computed)
Operating margin-873.9%3.7%-253.7%-519.8%
Net margin-764.0%1.5%-297.1%-511.9%
Net income-$412.78M$808.0K-$164.08M-$265.94M
EPS (Diluted)-$7.12$0.03-$9.73-$1.42
Operating cash flow-$372.98M$2.06M-$208.51M-$204.88M
Free cash flow-$377.29M$1.87M-$208.68M-$216.89M
Cash & equivalents$89.13M$3.62M$15.12M$737.06M
Total assets$1.30B$24.90M$280.41M$808.06M
Total liabilities$104.11M$4.58M$190.57M$153.75M
Shareholders' equity$1.19B$20.32M$89.83M$654.31M
Return on year-end equity-34.6%4.0%-182.6%-40.6%
Shares outstanding58.45M31.06M20.38M215.93M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearAgios Pharmaceuticals, Inc.Integrated Biopharma IncNektar TherapeuticsOcular Therapeutix, Inc
Latest$54.03M
Ended 2025-12-31
$54.35M
Ended 2025-06-30
$55.23M
Ended 2025-12-31
$51.95M
Ended 2025-12-31
1 year earlier$36.50M
Ended 2024-12-31
$50.32M
Ended 2024-06-30
$98.43M
Ended 2024-12-31
$63.72M
Ended 2024-12-31
2 years earlier$26.82M
Ended 2023-12-31
$50.67M
Ended 2023-06-30
$90.12M
Ended 2023-12-31
$58.44M
Ended 2023-12-31
3 years earlier$14.24M
Ended 2022-12-31
$56.25M
Ended 2022-06-30
$92.06M
Ended 2022-12-31
$51.49M
Ended 2022-12-31
4 years earlier$0
Ended 2021-12-31
$63.56M
Ended 2021-06-30
$101.91M
Ended 2021-12-31
$43.52M
Ended 2021-12-31